SCHEMBL3445304

SCHEMBL3445304

CCOC(=O)c1c(=O)c2cnc(SC)nc2n2c1sc1ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.39
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39
GABRB2 P47870 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRE P78334 2/20 0.39
GABRA6 Q16445 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31649261 0.87 KDM4E (0.42) MAPTALDH1A1POLBKDM4EHPGD
SCHEMBL31629442 0.87 KDM4E (0.42) MAPTALDH1A1POLBKDM4EHPGD
SCHEMBL3445568 0.86 KDM4E (0.38) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL31649287 0.83 CSNK1D (0.44) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL13046297 0.81 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2POLBTDP1
SCHEMBL31629507 0.81 KDM4E (0.43) MAPTALDH1A1KDM4EHPGDGABRP
SCHEMBL12254659 0.81 KDM4E (0.43) MAPTALDH1A1KDM4EHPGDGABRP
SCHEMBL31649027 0.81 KDM4E (0.43) MAPTALDH1A1POLBKDM4EHPGD
SCHEMBL31649019 0.81 RXFP1 (0.43) MAPTALDH1A1POLBKDM4EHPGD
SCHEMBL31649313 0.81 KDM4E (0.40) MAPTALDH1A1SMN1; SMN2POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816406-B2 Quinolone analogs CYLENE PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-7816406-B2 Quinolone analogs CYLENE PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-7816406-B2 Quinolone analogs CYLENE PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-20090291437-A1 METHODS FOR TARGETING QUADRUPLEX SEQUENCES CYLENE PHARMACEUTICALS, INC. 2009-11-26 US disclosed
US-20090291437-A1 METHODS FOR TARGETING QUADRUPLEX SEQUENCES CYLENE PHARMACEUTICALS, INC. 2009-11-26 US disclosed
WO-2007056113-A2 METHODS FOR TARGETING QUADRUPLEX SEQUENCES CYLENE PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed
US-20060074089-A1 Quinolone analogs SENHWA BIOSCIENCES, INC. (TW) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074089-A1 Quinolone analogs NQO2, BAX, MCL1 MAPT 4613/4885ALDH1A1 2050/4885SMN1; SMN2 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.